$Tempus AI (TEM.US)$ GeneCentric Therapeutics announced that...
GeneCentric Therapeutics announced that the American Medical Association has granted the PLA code for the purist pancreatic cancer test puristSM is an RNA expression-based test licensed to Tempus AI to provide information and personalize treatment for patients with pancreatic cancer. pURist's proprietary laboratory analysis (PLA) code is the first general procedural term (CPT) code created for the algorithm-based analysis of previously sequenced RNA data from laboratory-developed tests (LDT). GeneCentric Therapeutics, which makes precision medicine more accurate through RNA-based diagnosis, announced today that the American Medical Association (AMA) has granted a PLA code for puristSM pancreatic cancer testing. pURist is marketed under a collaboration agreement with Tempus AI, Inc. It runs on (NASDAQ:TEM) and its xR platform. The pURist PLA code is the first CPT code created to describe algorithm-only analysis from previously sequenced LDT, transcriptomic (RNA) data, and represents a meaningful step towards reimbursing AI-enabled algorithms. “The receipt of PURIST-specific PLA test code further supports the importance of GeneCentric's next-generation AI-derived testing pipeline,” said Dr. Michael Milburn, President and CEO of GeneCentric Therapeutics. “This is an important step towards successful reimbursement and commercialization of pURist, and we are excited about the importance of this test in guiding first-line treatment for patients with pancreatic cancer.” Pancreatic cancer has one of the highest mortality rates of all major cancers, and the availability of validated diagnostic tests or biomarkers to guide first choice is limited. The pURist test classifies tumors in patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma (PDAC) as a basal or classical subtype and helps guide first-line therapy. About the pURist test pURist identifies molecular subtypes of patients with unresectable stage III or stage IV PDAC, classifies patients with PDAC into basal or classical subtypes, and may help inform first-line therapy management. TEMPUS and GeneCentric recently completed a new clinical validation study demonstrating that PURIST can be used to predict classic patient overall survival between standard care first-line therapies, FOLFIRINOX and gemcitabinabinab paclitaxel. PURist tests can be ordered as part of an online Tempus HUB or via a paper request form for US orders. Providers and patients can learn more about the PURIST test on the Tempus website. About pancreatic cancer Pancreatic cancer is the 10th most commonly diagnosed cancer in the United States and the 12th most common cancer in the world. The National Cancer Institute estimates there will be more than 64,440 new cases and more than 51,750 deaths in the US alone in 2024, making it the third leading cause of cancer-related deaths in the US and one of the highest deaths among all major cancers. Over 90% of pancreatic cancers are pancreatic duct adenocarcinoma (PDAC), and the 5-year overall survival rates for resectable/border-resectable and unresectable PDACs are approximately 20% and 1-3%, respectively. The three main treatments for PDAC are surgical resection (if diagnosed early), radiation therapy, and chemotherapy. For resectable tumors, surgical removal is offered with curative intent, but chemotherapy such as FOLFIRINOX or gemcitabine containing nab-paclitaxel is often used for unresectable tumors. About GeneCentric GeneCentric Therapeutics, Inc., a leader in the development of RNA-based genomic biomarkers and next-generation companion diagnostics, is based in Durham, North Carolina. By analyzing the complexity of tumor biology using an RNA-based tumor and immune microenvironment (rT (I) ME) explorer platform and AI technology, they developed a deep pipeline of genetic signatures and associated diagnostic tests to identify populations responding to tumor treatments. Using the ExpressCT (Expression Signatures Through Tumor Signals) platform, these signatures can be applied to liquid biopsies. GeneCentric is commercializing its technology through preclinical trials, clinical drug development, and commercialization lifecycle phases, and through strategic collaborations with biopharmaceutical and diagnostic companies. For more details, seewww.genecentric.comGo to or follow us on LinkedIn. View source version on businesswire.com:https://www.businesswire.com/news/home/20240724151484/en/
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
